The Cytokine Release Syndrome Management market refers to the industry dedicated to managing and treating Cytokine Release Syndrome (CRS), a potentially life-threatening condition. As the Cytokine Release Syndrome Management market size is expected to grow significantly, driven by an increasing growth outlook and market forecast, the industry is poised for industry expansion. The scope of this market encompasses various treatment options, including tocilizumab, corticosteroids, and supportive care, catering to the needs of patients with CRS. According to recent estimates, the current Cytokine Release Syndrome Management market size is approximately $1.4 billion, with a projected CAGR of 8.5% from 2026 to 2033. The market growth is driven by macro drivers such as the rising incidence of cancer, increasing adoption of immunotherapy, and growing awareness about CRS. Key forces shaping the industry include technology shifts towards personalized medicine, regulations governing the use of immunotherapies, and competitive intensity among market players.